SN
DGX icon

Sittner & Nelson’s Quest Diagnostics DGX Stock Holding History

Sittner & Nelson’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.8K Hold
150
– – 0.01% 339
2026
Q1 		$29.4K Hold
150
– – 0.01% 343
2025
Q4 		$28.6K Buy
+150
New +$27.3K 0.01% 313
2021
Q1 		– Sell
-35
Closed -$4K – 410
2020
Q4 		$4K Buy
+35
New +$4.27K ﹤0.01% 331

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Sittner & Nelson's DGX Position: Q2 2026 in Review

Sittner & Nelson held its Quest Diagnostics (DGX) position steady in Q2 2026 at 150 shares worth $31.8K. The position accounts for 0.01% of the portfolio, ranked #339.

Sittner & Nelson first reported a position in DGX in Q4 2020 and has held it in 4 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Sittner & Nelson held 150 shares of Quest Diagnostics worth $31.8K as of Q2 2026.
  • Sittner & Nelson left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up 0.01% of Sittner & Nelson's portfolio in Q2 2026, its #339 holding.
  • Sittner & Nelson first reported a position in Quest Diagnostics in Q4 2020 and has held it in 4 quarters since.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.